◀ Back to MAP2K1

BCL2 — MAP2K1

Text-mined interactions from Literome

Lunghi et al., Leukemia 2005 (Leukemia, Promyelocytic, Acute) : MEK1 inhibitors dephosphorylated Bad and inhibited the ATO induced increase of Bcl-xL , overcoming ATO resistance in NB4-As ( R )
Nakamura et al., J Biol Chem 2006 (MAP Kinase Signaling System) : We found that MNSFbeta.Bcl-G directly bound to ERKs and inhibited ERK activation by MEK1
Ren et al., J Biol Chem 2007 (Leukemia, Myeloid...) : Shp2E76K induced Bcl-XL expression was suppressed by Mek inhibitors and by a dominant negative Mek1 mutant but not by the phosphoinositide 3-phosphate inhibitor LY294002 and the Akt inhibitor API-2
Elsegood et al., Arterioscler Thromb Vasc Biol 2009 : MEK1/2 and PI3K activities were also required for oxLDL induced Bcl-2 and Bcl-x ( L ) mRNA upregulation
Brinkkoetter et al., J Clin Invest 2009 (Glomerulonephritis) : Furthermore, we found that levels of phosphorylated MEK1/2 and ERK1/2 were decreased in cyclin I-deficient podocytes and that inhibition of MEK1/2 restored Bcl2 and Bcl-XL protein levels
Lucas et al., Biol Reprod 2010 : E2 and G-1 decreased BAX and increased BCL2 expression and these effects were blocked by MAP2K1/2 inhibitor and EGFR kinase inhibitor